PCG
DAWN

Private Capital Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Private Capital Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-142
Closed -$1K – 1927
2022
Q1 		$1K Buy
+142
New +$1.88K ﹤0.01% 1915

Other funds holding DAWN

CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Private Capital Group's DAWN Position: Q2 2022 in Review

Private Capital Group sold out of Day One Biopharmaceuticals (DAWN) in Q2 2022, closing a stake of 142 shares — an estimated $1K sold.

Private Capital Group first reported a position in DAWN in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 87 funds tracked by Wall St. Rank hold DAWN as of Q2 2022.

  • Private Capital Group reported no remaining Day One Biopharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 142 Day One Biopharmaceuticals shares in Q2 2022, an estimated $1K.
  • Private Capital Group first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Private Capital Group's Day One Biopharmaceuticals position peaked at $1K in Q1 2022.
  • 87 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.